Original articles｜Laboratories｜Cancer Chemotherapy Center

Update : 2017-06-15

Original articles

2017｜2016｜2015｜2014｜2013｜2012｜2011｜2010｜2009｜2008｜2007｜2006

2017

Hanaki Y, Kikumori M, Tokuda H, Okamura M, Dan S, Adachi N, Saito N, Yanagita RC, Irie K.: Loss of the Phenolic Hydroxyl Group and Aromaticity from the Side Chain of Anti-Proliferative 10-Methyl-aplog-1, a Simplified Analog of Aplysiatoxin, Enhances Its Tumor-Promoting and Proinflammatory Activities.
Molecules. 2017;22(4)

2016

Ohashi Y, Okamura M, Hirosawa A, Tamaki N, Akatsuka A, Wu KM, Choi HW, Yoshimatsu K, Shiina I, Yamori T, Dan S.: M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.
Cancer Res. 2016;76(13):3895-3903..
Akatsuka A, Kojima N, Okamura M, Dan S, Yamori T.: A novel thiophene-3-carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I.
Pharmacol Res Perspect. 2016;4(4):e00246..
Uesugi S, Fujisawa N, Yoshida J, Watanabe M, Dan S, Yamori T, Shiono Y, Kimura K.: Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition.
J Antibiot (Tokyo). 2016;69(3):133-140..
Takemoto Y, Ito A, Niwa H, Okamura M, Fujiwara T, Hirano T, Handa N, Umehara T, Sonoda T, Ogawa K, Tariq M, Nishino N, Dan S, Kagechika H, Yamori T, Yokoyama S, Yoshida M.: Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
J Med Chem. 2016;59(8):3650-3660..
Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.: Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Oncotarget. 2016;7(23):34811-34823..
Okada M, Mei ZW, Hossain MI, Tominaga T, Takebayashi T, Murakami M, Yasuda M, Shigehiro T, Kasai T, Mizutani A, Murakami H, El Sayed Iel T, Dan S, Yamori T, Seno M, Inokuchi T.: Synthesis and in vitro cancer cell growth inhibition evaluation of 11-amino-modified 5-Me-indolo[2,3-b]quinolines and their COMPARE analyses.
Med Chem Res. 2016;25(5):879-892..
Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.: Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
Eur J Med Chem. 2016;121:592-609..
Narita K, Katoh Y, Ojima K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.: Total Synthesis of the Depsipeptide FR901375 and Preliminary Evaluation of Its Biological Activity.
European Journal of Organic Chemistry 2016;34:5667-5677..
Matsumoto Y, Tsujimoto H, Ono S, Shinomiya N, Miyazaki H, Hiraki S, Takahata R, Yoshida K, Saitoh D, Yamori T, Yamamoto J, Hase K.: Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model.
Ann Surg Oncol. 2016;23 Suppl 2:257-265..
Hattori T, Watanabe-Takahashi M, Shiina I, Ohashi Y, Dan S, Nishikawa K, Yamori T, Naito M.: M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.
Genes Cells. 2016;21(8):901-906..

2015

Isoyama S, Kajiwara G, Tamaki N, Okamura M, Yoshimi H, Nakamura N, Kawamura K, Nishimura Y, Namatame N, Yamori T, Dan S.: Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.
Cancer Sci. 2015;106(2):171-178.
Morita M, Ogawa H, Ohno O, Yamori T, Suenaga K, Toyoshima C.: Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca(2+) pumps with a unique mode of binding.
FEBS Lett. 2015;589(13):1406-1411.
Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A.: Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Cancer Sci. 2015;106(7):909-920.
Kojima N, Suga Y, Matsumoto T, Tanaka T, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.: Synthesis of dansyl-labeled probe of thiophene analogue of annonaceous acetogenins for visualization of cell distribution and growth inhibitory activity toward human cancer cell lines.
Bioorg Med Chem. 2015;23(6):1276-1283.
Kawada M, Inoue H, Ohba S, Yoshida J, Masuda T, Yamasaki M, Usami I, Sakamoto S, Abe H, Watanabe T, Yamori T, Shibasaki M, Nomoto A.: Stromal cells positively and negatively modulate the growth of cancer cells: stimulation via the PGE2-TNFα-IL-6 pathway and inhibition via secreted GAPDH-E-cadherin interaction.
PLoS One. 2015;10(3):e0119415.
Iwasaki A, Ohno O, Katsuyama S, Morita M, Sasazawa Y, Dan S, Simizu S, Yamori T, Suenaga K.: Identification of a molecular target of kurahyne, an apoptosis-inducing lipopeptide from marine cyanobacterial assemblages.
Bioorg Med Chem Lett. 2015;25(22):5295-5298.
Ikeda K, Kamisuki S, Uetake S, Mizusawa A, Ota N, Sasaki T, Tsukuda S, Kusayanagi T, Takakusagi Y, Morohashi K, Yamori T, Dan S, Shiina I, Sugawara F.: Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factors.
Bioorg Med Chem. 2015;23(18):6118-6124.
Horii R, Matsuura M, Dan S, Ushijima M, Uehiro N, Ogiya A, Honma N, Ito Y, Iwase T, Yamori T, Akiyama F.: Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics.
Int J Clin Oncol. 2015;20(3):490-498.
Chen X, Tang SA, Lee E, Qiu Y, Wang R, Duan HQ, Dan S, Jin M, Kong D.: IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-kappaB and MAPK inactivation in RAW264.7 cells.
Life Sci. 2015;124:8-15.

2014

Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H, Takagi R, Shimizu T, Yamori T, Osada H, Noda T.: A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells.
Oncogene. 2014;33(33):4242-4252.
Tang SA, Zhou Q, Guo WZ, Qiu Y, Wang R, Jin M, Zhang W, Li K, Yamori T, Dan S, Kong D.: In vitro antitumor activity of stellettin B, a triterpene from marine sponge Jaspis stellifera, on human glioblastoma cancer SF295 cells.
Mar Drugs. 2014;12(7):4200-4213.
Momose I, Abe H, Watanabe T, Ohba S, Yamazaki K, Dan S, Yamori T, Masuda T, Nomoto A.: Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Cancer Sci. 2014;105(12):1609-1615.
Kong D, Yamori T, Yamazaki K, Dan S.: In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Invest New Drugs. 2014;32(6):1134-1143.
Kojima N, Fushimi T, Tatsukawa T, Tanaka T, Okamura M, Akatsuka A, Yamori T, Dan S, Iwasaki H, Yamashita M.: Thiophene-3-carboxamide analogue of annonaceous acetogenins as antitumor drug lead.
Eur J Med Chem. 2014;86C:684-689.
Jin M, Zhou Q, Lee E, Dan S, Duan HQ, Kong D.: AS252424, a PI3Kgamma Inhibitor, Downregulates Inflammatory Responsiveness in Mouse Bone Marrow-Derived Mast Cells.
Inflammation. 2014;37(4):1254-1260.
Fukui Y, Narita K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T.: Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity.
Eur J Med Chem. 2014;76:301-313.
Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I.: Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Mol Cancer Ther. 2014;13(11):2653-2661.

2013

Guo, W.Z., Shiina, I., Wang, Y., Umeda, E., Watanabe, C., Uetake, S., Ohashi, Y., Yamori, T., Dan, S.: Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway.
Biochem Pharmacol, 86, 1272-1284 (2013)
Guo, W.Z., Wang, Y., Umeda, E., Shiina, I., Dan, S., Yamori, T.: Search for novel anti-tumor agents from ridaifens using JFCR39, a panel of human cancer cell lines.
Biol Pharm Bull, 36, 1008-1016 (2013)
Hossain, M.I., Switalska, M., Peng, W., Takashima, M., Wang, N., Kaise, M., Wietrzyk, J., Dan, S., Yamori, T., Inokuchi, T.: Design, synthesis, and in vitro cancer cell growth inhibition evaluation and antimalarial testing of trioxanes installed in cyclic 2-enoate substructures.
Eur J Med Chem, 69C, 294-309 (2013)
Katayama, R., Aoyama, A., Yamori, T., Qi, J., Oh-Hara, T., Song, Y., Engelman, J.A., Fujita, N.: Cytotoxic activity of Tivanitib (ARQ 197) is not due solely to c-MET inhibition.
Cancer Res, 73, 3087-3096 (2013)
Kojima, N., Fushimi, T., Tatsukawa, T., Yoshimitsu, T., Tanaka, T., Yamori, T., Dan, S., Iwasaki, H., Yamashita, M.: Structure-activity relationships of hybrid annonaceous acetogenins: powerful growth inhibitory effects of their connecting groups between heterocycle and hydrophobic carbon chain bearing THF ring on human cancer cell lines.
Eur J Med Chem, 63, 833-839 (2013)
Komeda, S., Takayama, H., Suzuki, T., Odani, A., Yamori, T., Chikuma, M.: Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Metallomics, 5, 461-468 (2013)
Nagahara, Y., Takeyoshi, M., Sakemoto, S., Shiina, I., Nakata, K., Fujimori, K., Wang, Y., Umeda, E., Watanabe, C., Uetake, S., Yamori, T., Dan, S., Yoshimi, Y., Shinomiya, T., Ikekita, M.: Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement.
Biochem Biophys Res Commun, 435, 657-663 (2013)
Narita, K., Fukui, Y., Sano, Y., Yamori, T., Ito, A., Yoshida, M., Katoh, T.: Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities.
Eur J Med Chem, 60, 295-304 (2013)
Obuchi, W., Ohtsuki, S., Uchida, Y., Ohmine, K., Yamori, T., Terasaki, T.: Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics.
Mol Pharmacol, 83, 490-500 (2013)
Shiina, I., Umezaki, Y., Ohashi, Y., Yamazaki, Y., Dan, S., Yamori, T.: Total synthesis and anticancer activity of AMF-26 targeting ADP-ribosylation factor 1 (Arf1).
J Med Chem, 56, 150-159 (2013)
Ushijima, M., Mashima, T., Tomida, A., Dan, S., Saito, S., Furuno, A., Tsukahara, S., Seimiya, H., Yamori, T., Matsuura, M.: Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.
Cancer Sci, 104, 360-368 (2013)

2012

Isoyama, S., Dan, S., Nishimura, Y., Nakamura, N., Kajiwara, G., Seki, M., Irimura, T., Yamori, T.: Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Cancer Sci, 103, 1955-1960 (2012)
Shiina, I., Umezaki, Y., Ohashi, Y., Yamazaki, Y., Dan, S., Yamori, T.: Total Synthesis and Anticancer Activity of AMF-26 Targeting ADP-ribosylation Factor 1 (Arf1).
Journal of medicinal chemistry, in press (2012)
Ushijima, M., Mashima, T., Tomida, A., Dan, S., Saito, S., Furuno, A., Tsukahara, S., Seimiya, H., Yamori, T., Matsuura, M.: Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.
Cancer Sci, (2012)
Dan, S., Okamura, M., Mukai, Y., Yoshimi, H., Inoue, Y., Hanyu, A., Sakaue-Sawano, A., Imamura, T., Miyawaki, A., Yamori, T.: ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo.
Eur J Cancer, 48, 936-943 (2012)
Haruta, K., Mori, S., Tamura, N., Sasaki, A., Nagamine, M., Yaguchi, S., Kamachi, F., Enami, J., Kobayashi, S., Yamori, T., Takasaki, Y.: Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats.
Inflamm Res, 61, 551-562 (2012)
Isoyama, S., Yoshimi, H., Dan, S., Okamura, M., Seki, M., Irimura, T., Yamori, T.: Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Biol Pharm Bull, 35, 1607-1613 (2012)
Kaneko, M., Matsuda, D., Ohtawa, M., Fukuda, T., Nagamitsu, T., Yamori, T., Tomoda, H.: Potentiation of bleomycin in jurkat cells by fungal pycnidione.
Biol Pharm Bull, 35, 18-28 (2012)
Kimura, K., Sakamoto, Y., Fujisawa, N., Uesugi, S., Aburai, N., Kawada, M., Ohba, S., Yamori, T., Tsuchiya, E., Koshino, H.: Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants.
Bioorg Med Chem, 20, 3887-3897 (2012)
Kong, D., Yamori, T.: JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg Med Chem, 20, 1947-1951 (2012)
Miyazaki, T., Pan, Y., Joshi, K., Purohit, D., Hu, B., Demir, H., Mazumder, S., Okabe, S., Yamori, T., Viapiano, M., Shin-ya, K., Seimiya, H., Nakano, I.: Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
Clin Cancer Res, 18, 1268-1280 (2012)
Morita, M., Ohno, O., Teruya, T., Yamori, T., Inuzuka, T., Suenaga, K.: Isolation and structures of biselyngbyasides B, C, and D from the marine cyanobacterium Lyngbya sp., and the biological activities of biselyngbyasides.
Tetrahedron, 86, 5984 (2012)
Ohashi, Y., Iijima, H., Yamaotsu, N., Yamazaki, K., Sato, S., Okamura, M., Sugimoto, K., Dan, S., Hirono, S., Yamori, T.: AMF-26: a novel inhibitor of the Golgi system, targeting Arf1, an ADP-ribosylation factor 1, with potential for cancer therapy.
J Biol Chem, 287, 3885-3897 (2012)
Yao, R., Natsume, Y., Saiki, Y., Shioya, H., Takeuchi, K., Yamori, T., Toki, H., Aoki, I., Saga, T., Noda, T.: Disruption of Tacc3 function leads to in vivo tumor regression.
Oncogene, 31, 135-148 (2012)

2011

Anzai, K., Sekine-Suzuki, E., Ueno, M., Okamura, M., Yoshimi, H., Dan, S., Yaguchi, S.I., Enami, J., Yamori, T., Okayasu, R.: Effectiveness of combined treatment of X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo.
Cancer Sci, 102, 1176-1180 (2011)
Awale, S., Linn, T.Z., Li, F., Tezuka, Y., Myint, A., Tomida, A., Yamori, T., Esumi, H., Kadota, S.: Identification of Chrysoplenetin from Vitex negundo as a Potential Cytotoxic Agent against PANC-1 and a Panel of 39 Human Cancer Cell Lines (JFCR-39).
Phytother Res, 25, 1770-1775 (2011)
Donev, I.S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., Yano, S.: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Clin Cancer Res, 17, 2260-2269 (2011)
Fuwa, H., Suzuki, T., Kubo, H., Yamori, T., Sasaki, M.: Total synthesis and biological assessment of (-)-exiguolide and analogues.
Chemistry, 17, 2678-2688 (2011)
Kojima, N., Suga, Y., Hayashi, H., Yamori, T., Yoshimitsu, T., Tanaka, T.: Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines.
Bioorg Med Chem Lett, 21, 5745-5749 (2011)
Kong, D., Yamori, T., Kobayashi, M., Duan, H.: Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone.
Mar Drugs, 9, 154-161 (2011)
Kong, D., Zhang, Y., Yamori, T., Duan, H., Jin, M.: Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms.
Molecules, 16, 5159-5167 (2011)
Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M.R., Yamori, T., Nishiyama, N., Kataoka, K.: Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting.
Sci Transl Med, 3, 64ra62 (2011)

2010

Kojima, N., Morioka, T., Urabe, D., Yano, M., Suga, Y., Maezaki, N., Ohashi-Kobayashi, A., Fujimoto, Y., Maeda, M., Yamori, T., Yoshimitsu, T., Tanaka, T.: Convergent synthesis of fluorescence-labeled probes of Annonaceous acetogenins and visualization of their cell distribution.
Bioorg Med Chem, 18, 8630-8641 (2010)
Koyama, J., Morita, I., Yamori, T.: Correlation between cytotoxic activities and reduction potentials of heterocyclic quinones.
Molecules, 15, 6559-6569 (2010)
Laroche-Clary, A., Le Morvan, V., Yamori, T., Robert, J.: Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models.
Mol Cancer Ther, 9, 3315-3321 (2010)
Ueoka, R., Ise, Y., Ohtsuka, S., Okada, S., Yamori, T., Matsunaga, S.: Yaku'amides A and B, cytotoxic linear peptides rich in dehydroamino acids from the marine sponge Ceratopsion sp.
J Am Chem Soc, 132, 17692-17694 (2010)
Chou, L.C., Chen, C.T., Lee, J.C., Way, T.D., Huang, C.H., Huang, S.M., Teng, C.M., Yamori, T., Wu, T.S., Sun, C.M., Chien, D.S., Qian, K., Morris-Natschke, S.L., Lee, K.H., Huang, L.J., Kuo, S.C.: Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent.
J Med Chem, 53, 1616-1626 (2010)
Dan, S., Okamura, M., Seki, M., Yamazaki, K., Sugita, H., Okui, M., Mukai, Y., Nishimura, H., Asaka, R., Nomura, K., Ishikawa, Y., Yamori, T.: Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Cancer Res, 70, 4982-4994 (2010)
Hiramatsu, M., Ninomiya, H., Inamura, K., Nomura, K., Takeuchi, K., Satoh, Y., Okumura, S., Nakagawa, K., Yamori, T., Matsuura, M., Morikawa, T., Ishikawa, Y.: Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Lung Cancer, 70, 94-102 (2010)
Ihara, Y., Kihara, Y., Hamano, F., Yanagida, K., Morishita, Y., Kunita, A., Yamori, T., Fukayama, M., Aburatani, H., Shimizu, T., Ishii, S.: The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor.
Proc Natl Acad Sci U S A, 107, 17309-17314 (2010)
Kong, D., Dan, S., Yamazaki, K., Yamori, T.: Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Eur J Cancer, 46, 1111-1121 (2010)
Kong, D., Yamazaki, K., Yamori, T.: Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library.
Biol Pharm Bull, 33, 1600-1604 (2010)
Kong, D.X., Yamori, T.: ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.
Acta Pharmacol Sin, 31, 1189-1197 (2010)
Momose, I., Ohba, S., Tatsuda, D., Kawada, M., Masuda, T., Tsujiuchi, G., Yamori, T., Esumi, H., Ikeda, D.: Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions.
Biochem Biophys Res Commun, 392, 460-466 (2010)
Toyama, S., Tamura, N., Haruta, K., Karakida, T., Mori, S., Watanabe, T., Yamori, T., Takasaki, Y.: Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.
Arthritis Res Ther, 12, R92 (2010)
Yokosuka, A., Sato, K., Yamori, T., Mimaki, Y.: Triterpene glycosides from Curculigo orchioides and their cytotoxic activity.
J Nat Prod, 73, 1102-1106 (2010)

2009

Akashi, T., Yamori, T.: Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS.
Proteome Sci, 7, 14 (2009)
Dan, S., Yoshimi, H., Okamura, M., Mukai, Y., Yamori, T.: Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.
Biochem Biophys Res Commun, 379, 104-109 (2009)
Faur, N., Araud, L., Laroche-Clary, A., Kanno, J., Toutain, J., Yamori, T., Robert, J., Le Morvan, V.: The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.
Br J Cancer, 101, 350-356 (2009)
Kong, D., Okamura, M., Yoshimi, H., Yamori, T.: Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Eur J Cancer, 45, 857-865 (2009)
Kong, D., Yaguchi, S., Yamori, T.: Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Biol Pharm Bull, 32, 297-300 (2009)
Nakamura, T., Nakatsu, N., Yoshida, Y., Yamazaki, K., Dan, S., Sadahiro, S., Makuuchi, H., Yamori, T.: Identification of Candidate Genes Determining Chemosensitivity to Anti-cancer Drugs of Gastric Cancer Cell Lines.
Biological & Pharmaceutical Bulletin, 32, 1936-1939 (2009)
Narita, K., Kikuchi, T., Watanabe, K., Takizawa, T., Oguchi, T., Kudo, K., Matsuhara, K., Abe, H., Yamori, T., Yoshida, M., Katoh, T.: Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
Chemistry, 15, 11174-11186 (2009)
Nomura, T., Uehara, Y., Kawajiri, H., Ryoyama, K., Yamori, T., Fuke, Y.: Alkyl isothiocyanates suppress epidermal growth factor receptor kinase activity but augment tyrosine kinase activity.
Cancer Epidemiol, 33, 288-292 (2009)
Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., Miyata, N.: Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
J Med Chem, 52, 2909-2922 (2009)
Takahata, M., Inoue, Y., Tsuda, H., Imoto, I., Koinuma, D., Hayashi, M., Ichikura, T., Yamori, T., Nagasaki, K., Yoshida, M., Matsuoka, M., Morishita, K., Yuki, K., Hanyu, A., Miyazawa, K., Inazawa, J., Miyazono, K., Imamura, T.: SKI and MEL1 cooperate to inhibit transforming growth factor-β signal in gastric cancer cells.
J Biol Chem, 284, 3334-3344 (2009)

2008

Chen, C.J., Hsu, M.H., Huang, L.J., Yamori, T., Chung, J.G., Lee, F.Y., Teng, C.M., Kuo, S.C.: Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.
Biochem Pharmacol, 75, 360-368 (2008)
Kojima, N., Fushimi, T., Maezaki, N., Tanaka, T., Yamori, T.: Synthesis of hybrid acetogenins, alpha,beta-unsaturated-gamma-lactone-free nitrogen-containing heterocyclic analogues, and their cytotoxicity against human cancer cell lines.
Bioorg Med Chem Lett, 18, 1637-1641 (2008)
Kojima, N., Hayashi, H., Suzuki, S., Tominaga, H., Maezaki, N., Tanaka, T., Yamori, T.: Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines.
Bioorg Med Chem Lett, 18, 6451-6453 (2008)
Saito, H., Minamisawa, T., Yamori, T., Shiba, K.: Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria.
Cancer Sci, 99, 398-406 (2008)
Shiina, I., Sano, Y., Nakata, K., Kikuchi, T., Sasaki, A., Ikekita, M., Nagahara, Y., Hasome, Y., Yamori, T., Yamazaki, K.: Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents.
Biochem Pharmacol, 75, 1014-1026 (2008)
Sugita, H., Dan, S., Kong, D., Tomida, A., Yamori, T.: A new evaluation method for quantifying PI3K activity by HTRF assay.
Biochem Biophys Res Commun, 377, 941-945 (2008)
Wang, L., Bai, L., Tokunaga, D., Watanabe, Y., Hasegawa, T., Sakai, J., Tang, W., Bai, Y., Hirose, K., Yamori, T., Tomida, A., Tsuruo, T., Ando, M.: The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity.
J Wood Sci, 54, 390-401 (2008)

2007

Akashi, T., Nishimura, Y., Wakatabe, R., Shiwa, M., Yamori, T.: Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer.
Biochem Biophys Res Commun, 352, 514-521 (2007)
Akashi, T., Yamori, T.: A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins.
Proteomics, 7, 2350-2354 (2007)
Amagata, T., Tanaka, M., Yamada, T., Doi, M., Minoura, K., Ohishi, H., Yamori, T., Numata, A.: Variation in cytostatic constituents of a sponge-derived Gymnascella dankaliensis by manipulating the carbon source.
J Nat Prod, 70, 1731-1740 (2007)
Araki, H., Inoue, M., Suzuki, T., Yamori, T., Kohno, M., Watanabe, K., Abe, H., Katoh, T.: Enantioselective Total Synthesis of (+)-Ottelione A, (-)-Ottelione B, (+)-3-epi-Ottelione A and Preliminary Evaluation of Their Antitumor Activity.
Chemistry, 13, 9866-9881 (2007)
Hasegawa, T., Bai, J., Dai, J., Bai, L., Sakai, J., Nishizawa, S., Bai, Y., Kikuchi, M., Abe, M., Yamori, T., Tomida, A., Tsuruo, T., Hirose, K., Ando, M.: Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells.
Bioorg Med Chem Lett, 17, 3722-3728 (2007)
Ichikawa, K., Sakabe, E., Kuninobu, K., Yamori, T., Tsuruo, T., Yao, T., Tsuneyoshi, M., Utsumi, H.: Application of in vivo ESR/spin-probe technique to monitor tumor in vivo in mouse footpad.
Antioxid Redox Signal, 9, 1699-1707 (2007)
Inoue, A., Seino, Y., Terasaka, S., Hayashi, S., Yamori, T., Tanji, M., Kiyama, R.: Comparative profiling of the gene expression for estrogen responsiveness in cultured human cell lines.
Toxicol In Vitro, 21, 741-752 (2007)
Ishizu, K., Sunose, N., Yamazaki, K., Tsuruo, T., Sadahiro, S., Makuuchi, H., Yamori, T.: Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Biol Pharm Bull, 30, 1779-1783 (2007)
Ito, H., Iwasaki, J., Sato, Y., Aoyagi, M., Iguchi, K., Yamori, T.: Marine diterpenoids with a briarane skeleton from the Okinawan soft coral Pachyclavularia violacea.
Chem Pharm Bull (Tokyo), 55, 1671-1676 (2007)
Kong, D., Yamori, T.: ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms.
Cancer Sci, 98, 1638-1642 (2007)
Kuroda, M., Yokosuka, A., Kobayashi, R., Jitsuno, M., Kando, H., Nosaka, K., Ishii, H., Yamori, T., Mimaki, Y.: Sesquiterpenoids and flavonoids from the aerial parts of Tithonia diversifolia and their cytotoxic activity.
Chem Pharm Bull (Tokyo), 55, 1240-1244 (2007)
Matsuo, Y., Kanoh, K., Yamori, T., Kasai, H., Katsuta, A., Adachi, K., Shin-Ya, K., Shizuri, Y.: Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. I. Fermentation, isolation and biological activities.
J Antibiot, 60, 251-255 (2007)
Matsuoka, A., Isama, K., Tanimura, S., Kohno, M., Yamori, T.: A novel candidate compound with urethane structure for anticancer drug development.
Curr Drug Discov Technol, 4, 69-76 (2007)
Nakamura, H., Dan, S., Akashi, T., Unno, M., Yamori, T.: Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR.
Biol Pharm Bull, 30, 1181-1184 (2007)
Nakatsu, N., Nakamura, T., Yamazaki, K., Sadahiro, S., Makuuchi, H., Kanno, J., Yamori, T.: Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines.
Mol Pharmacol, 72, 1171-1180 (2007)
Yamaguchi, T., Yoshida, T., Kurachi, R., Kakegawa, J., Hori, Y., Nanayama, T., Hayakawa, K., Abe, H., Takagi, K., Matsuzaki, Y., Koyama, M., Yogosawa, S., Sowa, Y., Yamori, T., Tajima, N., Sakai, T.: Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor.
Cancer Sci, 98, 1809-1816 (2007)
Yokosuka, A., Haraguchi, M., Usui, T., Kazami, S., Osada, H., Yamori, T., Mimaki, Y.: Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells.
Bioorg Med Chem Lett, 17, 3091-3094 (2007)

2006

Kimura, H., Katoh, T., Kajimoto, T., Node, M., Hisaki, M., Sugimoto, Y., Majima, T., Uehara, Y., Yamori, T.: Modification of pyrimidine derivatives from antiviral agents to antitumor agents.
Anticancer Res, 26, 91-97 (2006)
Kishi, Y., Okudaira, S., Tanaka, M., Hama, K., Shida, D., Kitayama, J., Yamori, T., Aoki, J., Fujimaki, T., Arai, H.: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
J Biol Chem, 281, 17492-17500 (2006)
Nakamura, H., Kuroda, H., Saito, H., Suzuki, R., Yamori, T., Maruyama, K., Haga, T.: Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors.
ChemMedChem, 1, 729-740 (2006)
Tanaka, R., Wada, S., Yamada, T., Yamori, T.: Potent antitumor activity of 3,4-seco-8βH-Ferna-4(23),9(11)-dien-3-oic acid (EC-2) and 3,4-seco-Oleana-4(23),18-dien-3-oic acid (EC-4), evaluated by an in vitro human cancer cell line panel.
Planta Med, 72, 1347-1349 (2006)
Yaguchi, S., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., Yamori, T.: Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
J Natl Cancer Inst, 98, 545-556 (2006)

Contents

Original articles

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006